# PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

> **NCT02723877** · PHASE1,PHASE2 · COMPLETED · sponsor: **PIQUR Therapeutics AG** · enrollment: 41 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** PQR309
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT02723877
- **Lead sponsor:** PIQUR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-28
- **Primary completion:** 2018-10-03
- **Final completion:** 2018-10-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-03-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723877, "PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02723877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*